UPDATE — ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic
MIAMI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today...